Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Sep 30;18(1):257.
doi: 10.1186/s12957-020-02036-x.

Prognosis and risk factors for malignant peripheral nerve sheath tumor: a systematic review and meta-analysis

Zhenyu Cai  1 , Xiaodong Tang  1 , Haijie Liang  1 , Rongli Yang  1 , Taiqiang Yan  1 , Wei Guo  2
Affiliations
Meta-Analysis

Prognosis and risk factors for malignant peripheral nerve sheath tumor: a systematic review and meta-analysis

Zhenyu Cai et al. World J Surg Oncol. .

Abstract

Background: No available meta-analysis was printed to systematically introduce the MPNST clinic outcome and risk factors based on largely pooled data. This systematic review and meta-analysis aimed to investigate 5-year OS rate, 5-year EFS rate, and LR rate for MPNST, and to assess potential risk factors for prognosis.

Methods: Electronic articles published between January 1, 1966 and February 29, 2020 were searched and critically evaluated. The authors independently reviewed the abstracts and extracted data for 5-year OS rate, 5-year EFS rate, LR rate, and potential risk factors for prognosis.

Results: Twenty-eight literatures were finally included for meta-analysis. The pooled 5-year OS rate, 5-year EFS rate, and LR rate were 49%, 37%, and 38%, respectively. The significant prognostic factors for survival were NF1 status, tumor size, depth, location, malignant grade, margin status, chemotherapy, and radiotherapy. Age and sex were not associated with survival.

Conclusion: Survival and local recurrence of MPNST are poor. Worse prognosis is mainly associated with NF 1, large size, deep to fascia, high grade, metastases, and location (trunk and head and neck). Complete resection with adequate surgical margins is the mainstay protective factor of MPNST patients, following necessary adjuvant therapies.

Keywords: Local recurrence; Malignant peripheral nerve sheath tumor; Meta-analysis; Prognosis; Risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The flow chart showed the selection of studies for meta-analysis
See this image and copyright information in PMC

References

    1. Ducatman BS, Scheithauer BW, Piepgras DG. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006–2021. doi: 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6. - DOI - PubMed
    1. Vauthey JN, Woodruff JM, Brennan MF. Extremity malignant peripheral-nerve sheath tumors (neurogenic sarcomas)—a 10-year experience. Ann Surg Oncol. 1995;2:126–131. doi: 10.1007/BF02303627. - DOI - PubMed
    1. Wanebo JE, Malik JM, VandenBerg SR, Wanebo HJ, Driesen N, Persing JA. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer. 1993;71:1247–1253. doi: 10.1002/1097-0142(19930215)71:4<1247::AID-CNCR2820710413>3.0.CO;2-S. - DOI - PubMed
    1. Zhu B, Liu X, Liu Z, Yang S, Liao HI, Jiang L, Wei F. Malignant peripheral nerve sheath tumours of the spine: clinical manifestations, classification, treatment, and prognostic factors. Eur Spine J. 2012;21:897–904. doi: 10.1007/s00586-011-2093-y. - DOI - PMC - PubMed
    1. Bishop AJ, Zagars GK, Torres KE, Bird JE, Feig BW, Guadagnolo BA. Malignant peripheral nerve sheath tumors: a single institution's experience using combined surgery and radiation therapy. Am J Clin Oncol. 2018;41:465–470. doi: 10.1097/COC.0000000000000303. - DOI - PMC - PubMed